Francisco Amparo
About
In The Last Decade
Francisco Amparo
45 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 77
- Radiology, Nuclear Medicine and Imaging 876
- Public Health, Environmental and Occupational Health 800
- Ophthalmology 693
- Epidemiology 312
- Immunology and Allergy 172
Countries citing papers authored by Francisco Amparo
This map shows the geographic impact of Francisco Amparo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francisco Amparo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francisco Amparo more than expected).
Fields of papers citing papers by Francisco Amparo
This network shows the impact of papers produced by Francisco Amparo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francisco Amparo. The network helps show where Francisco Amparo may publish in the future.
Co-authorship network of co-authors of Francisco Amparo
This figure shows the co-authorship network connecting the top 25 collaborators of Francisco Amparo. A scholar is included among the top collaborators of Francisco Amparo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francisco Amparo. Francisco Amparo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 18 | |
| 2 | 12 | |
| 3 | 18 | |
| 4 | 45 | |
| 5 | 118 | |
| 6 | Vision-related Quality of Life in patients with Ocular Graft-Versus-Host Disease | 1 |
| 7 | Relative Efficacy of Loteprednol (Lotemax®) vs. Loteprednol-Tobramycin (Zylet®) on Corneal and Conjunctival Immune Response in Treatment of Meibomian Gland Dysfunction (MGD)-Associated Ocular Surface Inflammation: In Vivo Confocal Microscopy Results of a Phase IV Randomized Clinical Trial | 1 |
| 8 | 3 | |
| 9 | 57 | |
| 10 | 32 | |
| 11 | 85 | |
| 12 | Effect Of Topical IL-1RA On Signs And Symptoms Of Dry Eye Disease In Patients With Ocular Graft-versus-host Disease (GVHD) | 1 |
| 13 | 44 | |
| 14 | 24 | |
| 15 | 70 | |
| 16 | Sustained Efficacy of Topical Bevacizumab in the Treatment of Corneal Neovascularization (NV) | 2 |
| 17 | 65 | |
| 18 | 43 | |
| 19 | 29 | |
| 20 | 66 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.